Oncology Corporate Profile
This company does not have any pipeline products
6/14/2016 11:05 am
(Yahoo! Finance) June 14, 2016 - Celator Pharmaceuticals, Inc. today announced positive response rate results in AML patients with FLT3 (FMS-like tyrosine kinase-3) mutation were presented at the European Hematology Association (EHA) 21st Annual Congress. The results are from the Company's Phase 3 trial of VYXEOS™ (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML).
5/20/2016 11:03 am
(San Diego Union-Tribune) May 19, 2016 - A drug in clinical trials for liver diseases by a San Diego biotech company may be useful in treating acute myeloid leukemia, according to research published this week.
5/18/2016 11:05 am
(ASCO in Action) May 17, 2016 - The oncology community voiced its strong opposition to the proposed Medicare Part B demonstration project today on Capitol Hill before the Health Subcommittee of the House Energy and Commerce Committee.
5/4/2016 07:00 am
(StreetInsider) May 3, 2016 - Acceptance reinforces significant unmet need for difficult-to-treat type of pediatric acute lymphoblastic leukemia.
4/14/2016 11:04 am
(Washington Post/To Your Health) Apr 13, 2016 - Federal health officials confirmed Wednesday that the Zika virus causes a rare birth defect and other severe fetal abnormalities, marking a turning point in an epidemic that has spread to more than 40 countries and territories in the Americas and elsewhere.
4/12/2016 12:01 pm
(Medscape Medical News) Apr 12, 2016 - Most doctors do not fully understand the drug approval process for the US Food and Drug Administration (FDA) or the FDA's "breakthrough" drug classification, according to a survey published April 12 in JAMA.
4/1/2016 10:05 am
(Forbes) Mar 31, 2016 - Scientists have shown that an unusual form of genetic material can help cause blood cancers.
2/23/2016 01:01 pm
(Xconomy New York) Feb 23, 2016 - Two times, PTC Therapeutics has asked the FDA to look at an application to approve a Duchenne muscular dystrophy drug it’s been developing. And now two times, the agency has sent the South Plainfield, NJ-based company back to the drawing board.
6/11/2015 11:03 am
(BMS) June 11, 2015 - Bristol-Myers Squibb will present data for elotuzumab, an investigational immunostimulatory antibody, in relapsed or refractory multiple myeloma; Opdivo (nivolumab), in patients with relapsed or refractory lymphoid malignancies; and Sprycel (dasatinib), in chronic myeloid leukemia.
6/2/2015 04:05 pm
(Synta) June 2, 2015 - Synta Pharmaceuticals Corp. today announced updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90.
5/31/2015 07:00 pm
(Benzinga) May 31, 2015 - Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA®) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.
5/31/2015 07:00 pm
(MarketWatch) May 31, 2015 - A combination of Biothera’s Imprime PGG and the monoclonal antibodies alemtuzumab and rituximab achieved responses in 13 of 14 (93%) patients with high-risk chronic lymphocytic leukemia, including nine (64%) complete responses. Results of this phase 1/2 study will be presented today at the American Society of Clinical Oncology (ASCO).
5/29/2015 02:02 pm
(Moffitt) May 28, 2015 - The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients.
4/29/2015 11:05 am
(Washington Post) Apr 29, 2015 - Last week, my colleagues and I, as part of the U.S. Preventive Services Task Force, shared new draft recommendations on breast cancer screening. Our recommendations are based on an in-depth review of the strongest available science regarding mammography.
4/21/2015 11:04 am
(The Guardian [UK]) Apr 21, 2015 - Dietary supplements, such as over-the-counter multivitamins, do “more harm than good” and can increase the risk of developing cancer and heart disease, according to research in the US.
4/13/2015 11:04 am
(University of Michigan) Apr 13, 2015 - University of Michigan researchers have discovered a biomarker that may be a potentially important breakthrough in diagnosing and treating prostate cancer.
4/9/2015 12:03 pm
(Health Affairs blog) Apr 8, 2015 - Drug shortages are a significant public health issue that have affected many critically important drugs including chemotherapy treatments, nutritional support preparations, and antibiotics.
3/27/2015 11:02 am
(ASH) Mar 25, 2015 - Today Representatives David McKinley (R-WV) and Lois Capps (D-CA) introduced the Patients’ Access to Treatments Act in the House of Representatives, an important first step toward removing the burden of excessive cost-sharing for Americans who need high-cost, specialty-tier medications.
3/12/2015 12:01 pm
(California Healthline) Mar 12, 2015 - House and Senate leaders are discussing a permanent fix for Medicare's sustainable growth rate formula, lawmakers and aides said Wednesday, the Wall Street Journal reports (Peterson/Radnofsky, Wall Street Journal, 3/11).
2/27/2015 12:00 pm
(MSKCC/OnCancer blog) Feb 26, 2015 - Surgery is the most common treatment for people with rectal cancer, but an operation is just the first step when it comes to restoring quality of life.
1/12/2015 11:03 am
(Bloomberg) Jan 10, 2015 - The hottest area in cancer drugs is going mainstream this year.
1/7/2015 03:02 pm
(Nasdaq) Jan 7, 2015 - Sandoz, a Novartis company, announced today that US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of its investigational biosimilar filgrastim in the US.
1/6/2015 11:04 am
(Scientific American/Nature magazine) Jan 5, 2015 - A mammoth US effort to genetically profile 10,000 tumours has officially come to an end.
12/22/2014 11:04 am
(CNBC) Dec 22, 2014 - Express Scripts says its largest plan will cover only AbbVie's hepatitis C regimen, excluding drugs from Gilead and J&J.
12/10/2014 03:03 pm
(Loyola Health Sciences) Dec 10, 2014 - Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.